Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protara Therapeutics, Inc.TARA · Entity 6203 | Chief R&D Officer | April 08, 2026 | April 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protara Therapeutics, Inc.
Report date April 08, 2026 · Filed April 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 94,827 |
Reported balance
After 2026-04-08 transaction · row 1
1 source rowRow 1 · 2026-04-08 · Sale · Disposed 1,134 · Balance 94,827 F1: The sale reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 31, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 08, 2026 Filed Apr 9, 2026 21:25 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 1,134 | $5.40 | $6,123.60 |
DisclosureSEC source: 0001213900-26-042079 · marketforms-72911.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,827 F1 · shares: The sale reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 31, 2025. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 22,598 | $5.26 | $118,865.48 |
DisclosureSEC source: 0001213900-26-039328 · marketforms-72854.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,961 F1 · shares: The sale reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 31, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.31, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 3,724 | $6.67 | $24,839.08 |
DisclosureSEC source: 0001213900-26-008223 · marketforms-71933.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,559 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 24, 2025. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:30 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 6,578 | $5.60 | $36,836.80 |
DisclosureSEC source: 0001213900-26-006708 · marketforms-71770.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,283 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on January 19, 2023 and January 19, 2024. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:36 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001213900-26-006225 · marketforms-71895.xml · derivative · entry 2 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2036-01-15 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:36 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-006225 · marketforms-71895.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,861 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:12 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 21,224 | $4.53 | $96,144.72 |
DisclosureSEC source: 0001013762-25-004101 · marketforms-68923.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,861 F1 · shares: The sale reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 23, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.41 to $4.69, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 146,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001213900-25-007532 · marketforms-67931.xml · derivative · entry 2 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,000 Underlying: Common Stock · 146,000 shares Expires 2035-01-23 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 24, 2025 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 24,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-007532 · marketforms-67931.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,639 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 24, 2025. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 6,554 | $4.76 | $31,197.04 |
DisclosureSEC source: 0001213900-25-005963 · marketforms-67894.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,585 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on January 19, 2023 and January 19, 2024. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:20 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 2,157 | $6.14 | $13,243.98 |
DisclosureSEC source: 0001213900-25-001646 · marketforms-67734.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,139 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 3, 2022. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 137,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001213900-24-005724 · marketforms-64336.xml · derivative · entry 3 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,000 Underlying: Common Stock · 137,000 shares Expires 2034-01-18 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 19, 2024 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 3,049 | $1.91 | $5,823.59 |
DisclosureSEC source: 0001213900-24-005724 · marketforms-64336.xml · nonDerivative · entry 2 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,296 F3 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 19, 2023. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-005724 · marketforms-64336.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,345 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2024. Read SEC document |
| January 10, 2024 Filed Jan 12, 2024 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 5,229 | $2.39 | $12,497.31 |
DisclosureSEC source: 0001213900-24-003335 · marketforms-64051.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,345 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 10, 2020. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:35 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 1,899 | $2.17 | $4,120.83 |
DisclosureSEC source: 0001213900-24-001546 · marketforms-63997.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,574 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 3, 2022. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 21:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 119,300 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001213900-23-004082 · ownership.xml · derivative · entry 2 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,300 Underlying: Common Stock · 119,300 shares Expires 2033-01-18 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 19, 2023 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 21:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 19,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-004082 · ownership.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,473 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2023. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 5,225 | $3.00 | $15,675.00 |
DisclosureSEC source: 0001213900-23-002266 · ownership.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,573 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 10, 2020. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:26 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 2,159 | $2.80 | $6,045.20 |
DisclosureSEC source: 0001213900-23-000857 · ownership.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,798 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 3, 2022. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 22:20 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 4,603 | $6.27 | $28,860.81 |
DisclosureSEC source: 0001209191-22-003091 · doc4.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,957 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 10, 2020. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:37 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 84,800 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001209191-22-001725 · doc4.xml · derivative · entry 2 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,800 Underlying: Common Stock · 84,800 shares Expires 2032-01-02 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 3, 2022 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:37 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 14,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001725 · doc4.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,560 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 3, 2022. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 20:04 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $19.82 | $0.00 |
DisclosureSEC source: 0001209191-21-004652 · doc4.xml · derivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-01-18 F1 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 19, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:19 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 4,653 | $21.16 | $98,457.48 |
DisclosureSEC source: 0001209191-21-003448 · doc4.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Chf Scientific Operations Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,460 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 10, 2020. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 00:11 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 45,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003233 · doc4.xml · nonDerivative · entry 2 Zummo Jacqueline · CIK 0001798929 · Sr. Vice President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,113 F3 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of Issuer's common stock. 25% of the shares vest on each one-year anniversary of January 10, 2020. Read SEC document |
| January 09, 2020 Filed Jan 14, 2020 00:11 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 9,537 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-003233 · doc4.xml · derivative · entry 5 Zummo Jacqueline · CIK 0001798929 · Sr. Vice President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,537 Underlying: Common Stock · 9,537 shares Expires 2019-09-16 F1 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F7 · price: Received in the Merger in exchange for an employee stock option to acquire 50,000 shares of ArTara Sub Common Stock for $1.75 per share. F8 · derivative.exercise_date: 22,000 (44%) of the shares subject to the option shall vest immediately. The remaining 28,000 shares shall vest in twenty seven (27) approximately equal increments beginning on the first day of the first calendar month following the Date of Grant, September 17, 2019, and then on the first day of each of the next twenty six (26) months thereafter a ("Vesting Date"), if Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being December 1, 2021, all of the Option Shares which had not vested by then will vest and become exercisable). Read SEC document |
| January 09, 2020 Filed Jan 14, 2020 00:11 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 9,537 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-003233 · doc4.xml · derivative · entry 4 Zummo Jacqueline · CIK 0001798929 · Sr. Vice President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,537 Underlying: Common Stock · 9,537 shares Expires 2028-12-31 F1 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F7 · price: Received in the Merger in exchange for an employee stock option to acquire 50,000 shares of ArTara Sub Common Stock for $1.75 per share. F6 · derivative.exercise_date: The shares subject to the option shall vest in forty eight (48) approximately equal increments of one thousand forty one (1,041) shares beginning on the first day of the first calendar month following January 1, 2019, and then on the first day of each of the next forty seven (47) months thereafter (each a "Vesting Date"), if Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being December 1, 2022), all of the Option Shares which had not vested by then (being not less than 1,073 Option Shares) will vest and become exercisable. Read SEC document |
| January 09, 2020 Filed Jan 14, 2020 00:11 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 19,075 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-003233 · doc4.xml · derivative · entry 3 Zummo Jacqueline · CIK 0001798929 · Sr. Vice President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,075 Underlying: Common Stock · 19,075 shares Expires 2028-07-11 F1 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F5 · price: Received in the Merger in exchange for an employee stock option to acquire 100,000 shares of ArTara Sub Common Stock for $1.75 per share. F4 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly following August 1, 2018, for so long as the Reporting Person provides continuous service to the Issuer. Read SEC document |
| January 09, 2020 Filed Jan 14, 2020 00:11 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 28,613 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-003233 · doc4.xml · nonDerivative · entry 1 Zummo Jacqueline · CIK 0001798929 · Sr. Vice President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,613 F1 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F2 · price: These shares were received in exchange for 150,000 shares of ArTara Sub Common Stock in connection with the Merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.